Marisa Wexler, MS, senior science writer —

The U.S. Food and Drug Administration (FDA) has granted SoniVie permission to begin a pivotal clinical trial of its Therapeutic Intra-Vascular Ultrasound (TIVUS) System in people with pulmonary arterial hypertension (PAH). This “study will provide important information on the safety and efficacy of the TIVUS System in…

The combination of Opsumit (macitentan) and Adcirca (tadalafil) is a safe and effective initial treatment for pulmonary arterial hypertension (PAH), new clinical trial data show. The findings were published in the European Respiratory Journal, in the study, “Initial combination therapy of macitentan and tadalafil…

The U.S. Food and Drug Administration (FDA) has accepted for review the  application for Tyvaso (inhaled treprostinil) as a potential treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The supplemental new drug application (sNDA) was submitted by United Therapeutics,…

High pulmonary vascular resistance (PVR) is associated with worse mortality rates among people with pulmonary hypertension (PH), and the bottom threshold for what constitutes “elevated” PVR is lower than previously thought, a new study suggests. “The findings of this study cast the clinical profile of patients who have PH and…

People with pulmonary arterial hypertension (PAH) who are treated at specialty care centers have better survival chances and a lower likelihood of hospitalization, a study reports. These findings support referring PAH patients to specialty care centers for treatment, where factors like more careful disease monitoring might be decisive. The…

U.S. veterans with pulmonary hypertension (PH) due to left heart disease and chronic lung disease are more likely to be inappropriately prescribed phosphodiesterase-5 inhibitors (PDE5i) if they have received care both in and out of the Veterans Health Administration (VA), a study has found. Other factors for…

At-home treatment with inhaled nitric oxide through Genosyl, a tankless delivery system, was used successfully to manage pulmonary arterial hypertension (PAH) complicated by COVID-19 in a patient, according to a case study. The case was described in the report “Outpatient Inhaled Nitric Oxide in a…

LIQ861, Liquidia Technology‘s investigational inhaled formulation of treprostinil, is safe and well-tolerated in patients with pulmonary arterial hypertension (PAH), according to final results from a Phase 3 clinical trial. The trial results supported the new drug application…

The Pulmonary Hypertension Association (PHA) will be participating in a fundraiser for World PH Day on May 5. World PH Day is an annual event that started in 2012 and seeks to raise awareness about PH. Around the world, more than 80 organizations —  including the…

Reata Pharmaceuticals is stopping clinical trials evaluating bardoxolone methyl in people with pulmonary arterial hypertension (PAH), including a Phase 3 study, to ensure the safety of participants during the COVID-19 pandemic, the company announced. Trials in other disorders are set to continue, although some will stop…

The first person with coronavirus disease 2019 (COVID-19) complicating pulmonary hypertension (PH) has received at-home treatment with inhaled nitric oxide (iNO), delivered through the Genosyl system, according to VERO Biotech, manufacturer of Genosyl. The PH patient with COVID-19 infection was treated under the terms of an emergency…

Treatment with Orenitram (oral treprostinil) is associated with lower healthcare-related costs than treatment with Uptravi (selexipag) in people with pulmonary arterial hypertension (PAH), a new study suggests. The study, “Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective…